A randomized double-blinded placebo-controlled crossover trial of nebulized taurolidine in adult cystic fibrosis patients infected with Burkholderia cepacia

Journal of Aerosol Medicine: Deposition, Clearance, and Effects in the Lung

Volumn 15, Issue 1, 2002, Pages 51-57

  Ledson, Martin J ^a   Gallagher, Malcolm J ^a   Robinson, Maxine ^a   Cowperthwaite, Carolyn ^a   Williets, Trevor ^a   Hart, Charles A ^a   Walshaw, Martin J ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Inhaled antibacterial agents; Resistant pathogens

Indexed keywords

PLACEBO; TAUROLIDINE;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COUNT; BURKHOLDERIA CEPACIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYSTIC FIBROSIS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EPIDEMIC; HUMAN; NEBULIZATION; SPIROMETRY; UNITED KINGDOM;

EID: 0036223381     PISSN: 08942684     EISSN: None     Source Type: Journal    
DOI: 10.1089/08942680252908575     Document Type: Article

References (38)

1. Pseudomonas cepacia infection in cystic fibrosis: An emerging problem
2. Burkholderia cepacia colonisation in patients with cystic fibrosis: Risk factors and clinical outcome
3. Effects of Pseudomonas aeruginosa colonisation on survival and pulmonary function of cystic fibrosis patients
4. Pseudomonas cepacia in adult cystic fibrosis: Accelerated decline in lung function and increased mortality
5. Respiratory tract colonisation with Pseudomonas aeruginosa in cystic fibrosis. Correlations between anti-Pseudomonas anti-body levels and pulmonary function
6. Outcome of Burkholderia cepacia colonisation in children with cystic fibrosis following a hospital out-break
7. Determinants of mortality from cystic fibrosis in Canada 1970-1989
8. Outcome for patients colonised with Burkholderia cepacia in a Birmingham adult cystic fibrosis clinic at the end of an epidemic
9. Morbidity and mortality associated with B. cepacia colonisation in an adult CF centre
10. Taurolidine in adult cystic fibrosis patients colonised with epidemic Burkholderia cepacia
11. Reduced adherance of microorganisms to human mucosal epithelial cells following treatment with taurolin, a novel microbial agent
12. Investigation of endotoxin inactivation in plasma; pre-liminary results of a controlled randomised study on taurolin as a supplemental therapeutic agent in septicaemia
13. Drug delivery systems
14. Aerosol antibiotic treatment in cystic fibrosis
15. Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis
16. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment
17. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis
18. Efficacy of aerosolized tobramycin in patients with cystic fibrosis
19. Aerosolised amikacin administration to cystic fibrosis patients chronically infected with Pseudomonas aeruginosa
20. Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa
21. Effect of inhaled azlocillin, mistrabanon and combination therapy in children with cystic fibrosis
22. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis
23. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection
24. Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: A meta-analysis of benefits and risks
25. Type characterisation and antibiotic susceptibility of Burkholderia (Pseudomonas) cepacia isolates from patients with CF in the U.K. and Republic of Ireland
26. Polymyxin B, colistin and sodium colistimethate
27. A controlled trial of nebulised aminoglycoside and oral flucloxacillin versus placebo in the outpatient management of children with cystic fibrosis
28. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonised with Pseudomonas aeruginosa
29. Nebulised gentamicin in children and adolescents with cystic fibrosis
30. Microbial pathogenesis in cystic fibrosis: Mucoid Pseudomonas aeruginosa and Burkholderia cepacia
31. Pseudomonas cepacia adherence to respiratory epithelial cells is enhanced by Pseudomonas aeruginosa
32. Identification of the mucin-binding adhesion of Pseudomonas cepacia isolated from patients with cystic fibrosis
33. Nebulised taurolidine and B. cepacia bronchiectasis